Learning objectives
The Educational Training Programme is composed of 8 sessions aiming at:
- Understanding clinically-relevant mechanisms of action (haemostatic and pharmacological) underlying the most recent and effective combined antithrombotic strategies in atherothrombotic and venous thromboembolic diseases;
- Managing atherothrombotic diseases in the chronic and acute settings, in special patient populations such as diabetic, chronic kidney disease, pregnant, obese, older and/or frail patients who remain an unmet clinical need in spite of the most recent evidence;
- Managing cardioembolic and venous thromboembolic diseases in the chronic and/or acute settings, with a special focus on cancer patients.
Programme
Faculty members list:
Working Group on Aorta & Peripheral Vascular Diseases (WGA-PVD)
- Victor Aboyans- Chair
- Marco De Carlo- Past Chair
- Lucia Mazzolai- Vice Chair
- Oliver Schlager- Treasurer
- Marianne Brodmann
- Christine Espinola-Klein
- José Rodriguez-Palomares
- Emmanuel Messas
- Dimitrios Terentes-Printzios
Working Group on Thrombosis (WGT)
- Dirk Sibbing- Chair
- Bianca Rocca- Past Chair
- Gemma Vilahur- Vice Chair
- Andrea Rubboli- Treasurer
- Diana Gorog
- Rob Storey
- Jean Philippe Collet
- Joao Morais
- Tobias Geisler
Special Guest: Lars Wallentin
Wednesday 12 June
13:00-14:30: Registration and lunch
14:30-14:50: Welcome message from the Working Groups Chairpersons - V Aboyans and D Sibbing
14:50-16:20: Session 1
Focus on the pathophysiology of endothelium and haemostasis / thrombosis
Chairs: V Aboyans and D Sibbing
- Platelets and atherothrombosis - B Rocca
- Endothelial function and biomarkers in PAD - D Terentes-Printzios
- Factor Xa: a crossroad between coagulation and platelet - T Geisler
- Novel targets in the coagulation pathway - D Gorog
16:20-16:45: Networking
16.45-18.15: Session 2
Antithombotic strategies in peripheral arteries
Chairs: M Brodmann and O Schlager
- Antithrombotic strategies in carotid artery disease. Lucia Mazzolai
- Dual antithrombotic therapies in stable patients with PAD. C Espinola-Klein
- DAPT after peripheral revascularization. M De Carlo
- AF & PAD: a non-random association. V Aboyans
18.30-19.00: Lecture
Antithrombotic therapies: how to assess bleeding risk and its severity?
Chairs: V Aboyans and D Sibbing
Lecturer: Lars Wallentin
19.00-20.30: Networking cocktail at the Heart House
Thursday 13 June
Morning sessions
09:00-10:30: Session 1
Combined antithrombotic strategies in CAD
Chairs: D Sibbing and T Geisler
- Update on DAPT in the first year after ACS - R Storey
- Dual antithrombotic strategy in stable CAD: for whom? - D Sibbing
- Antithrombotic and antiplatelet agents one-year post-MI: how many options? - T Geisler
- Atrial Fibrillation in stable CAD and ACS - A Rubboli
10:30-11:00: Networking
11:00-12:30: Session 2
Antithrombotic therapies in special populations
Chairs: D Gorog and M De Carlo
- Antithrombotic therapies in acquired and congenital thrombophilic disorders? - L Mazzolai
- Antithrombotic therapies in pregnancy - M Brodmann
- Antithrombotic therapies in CKD - D Gorog
- Antithrombotic therapies in the old/frail patients - E. Messas
12:30-14:00: Lunch and networking
Afternoon sessions
14:00-15:30: Session 1
Antithrombotic therapies and diabetes and/or metabolic syndrome
Chairs: J Rodriguez-Palomares and B Rocca
The haemostatic imbalance in type 2 diabetes and Metabolic Syndrome - G Vilahur Garcia
Antithrombotic strategies in diabetic patients with CAD - M De Carlo
Antithrombotic strategies in diabetic patients with PAD - C Espinola-Klein
Obesity and antithrombotic strategies in arterial and venous diseases - R Storey
15.30-16:00: Networking
16:00-17:30: Session 2
Focus on venous thromboembolism
Chairs: A Rubboli and E Messas
- Prevention of VTE: when and how? Joao Morais
- PE, DVT and SVT: current management. M Brodmann
- Long-term anticoagulation after PE/DVT: when and how? C Espinola-Klein
- Prevention and treatment of post-thrombotic syndrome. O Schlager
17:30-18:00: Networking
18:00-18:40: Debate Session
Antithrombotic strategies in asymptomatic patients: Pros and Cons
Chairs: J Morais and D Terentes-Printzios
- Antithrombotic therapy is indicated in Primary Prevention (pro) - B Rocca
- Antithrombotic therapy is indicated in Primary Prevention (contra) - V Aboyans
- Rebuttal - B Rocca
- Rebuttal - V Aboyans
18:40: Wrap up
Friday 14 June
09:00-10:30: Session 1
Focus on venous thromboembolism and cancer
20 min +10 common discussion at the end
Chairs: C Espinola-Klein and G Vilahur Garcia
- Haemostasis and thrombosis in cancer - G Vilahur Garcia
- Coronary and stroke events in patients with cancer - J Morais
- Management of VTE in patients with cancer - O Schlager
- Looking for cancer after VTE? When and how? - E. Messas
10:30-10:45: Networking
10:45-12:15: Session 2
Antithrombotic therapies and cardiovascular devices
20 min +10 common discussion at the end
Chairs: T Geisler and D Terentes-Printzios
- PFO closure: indications and antithrombotic strategy after implantation - JP Collet
- Left atrial appendage occlusion: indications and antithrombotic strategy thereafter - A Rubboli
- TAVI, SAVI and antithrombotic strategies thereafter - D Sibbing
- Aortic diseases, TEVAR, EVAR and antithrombotic strategies - J Rodriguez-Palomares
12:15-12:30: Closing remarks - V Aboyans and G Vilahur Garcia